Genetic Survey of Psilocybe Natural Products
Sebastian Dörner, Kai Rogge, Janis Fricke, Tim Schäfer, Jacob M. Wurlitzer, Markus Gressler, Duyen N. K. Pham, David R. Manke, Andrew R Chadeayne, Dirk Hoffmeister
ChemBioChem May 18, 2022 DOI: 10.1002/cbic.202200249 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Genomic analysis Peer reviewed |
|---|---|
| Population | Five Psilocybe species (P. azurescens, P. cubensis, P. cyanescens, P. mexicana, and P. serbica) |
| Keywords | Metabolome Natural product Metabolite Metabolomics |
| Citations | 43 |
| Key points | The genomes of five Psilocybe species revealed a much greater and unexplored metabolic diversity than evident from chemical analyses, including identification of aeruginascin producers and detection of lumichrome and verpacamide A. |
Abstract
Abstract Psilocybe magic mushrooms are best known for their main natural product, psilocybin, and its dephosphorylated congener, the psychedelic metabolite psilocin. Beyond tryptamines, the secondary metabolome of these fungi is poorly understood. The genomes of five species ( P. azurescens , P. cubensis , P. cyanescens , P. mexicana , and P. serbica ) were browsed to understand more profoundly common and species‐specific metabolic capacities. The genomic analyses revealed a much greater and yet unexplored metabolic diversity than evident from parallel chemical analyses. P. cyanescens and P. mexicana were identified as aeruginascin producers. Lumichrome and verpacamide A were also detected as Psilocybe metabolites. The observations concerning the potential secondary metabolome of this fungal genus support pharmacological and toxicological efforts to find a rational basis for yet elusive phenomena, such as paralytic effects, attributed to consumption of some magic mushrooms.
Citations in the library
Cited by 35
- Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice ACS Pharmacology & Translational Science November 2, 2022
- The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology International Journal of Molecular Sciences January 10, 2023
- Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain. Molecular Psychiatry July 1, 2024
- A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond Biotechnology Advances August 31, 2023
- Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster Proceedings of the National Academy of Sciences January 9, 2024
and 30 more in the library
Cites 31
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Psilocybin – Summary of knowledge and new perspectives European Neuropsychopharmacology December 17, 2013
- Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen Helvetica Chimica Acta 1959
- Enzymatic Synthesis of Psilocybin Angewandte Chemie International Edition August 1, 2017
and 26 more in the library